-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The PARP inhibitor (PARPi) Olaparib has been approved as a maintenance therapy for advanced pancreatic cancer (PC) carrying germline pathogenic mutations (PV) of BRCA1 or BRCA2 genes .
Pancreatic cancer
This is a single-arm phase 2 clinical trial initiated by investigators to evaluate another PARPi, rucaparib, as a maintenance therapy for carrying BRCA1, BRCA2 or PALB2 gene systems or germline pathogenicity The role of mutant advanced pancreatic cancer .
To evaluate the role of another PARPi, rucaparib, as a maintenance therapy for advanced pancreatic cancer carrying BRCA1, BRCA2 or PALB2 gene system or germline pathogenic mutations
Recruitment conditions of test patients: advanced pancreatic cancer, carrying germline (g) or system (s) BRCA1, BRCA2 or PALB2 gene pathogenic mutations, receiving platinum-based chemotherapy for at least 16 weeks and no signs of platinum resistance .
A total of 46 patients were recruited, of which 42 were evaluable ( 27 with gBRCA2, 7 with gBRCA1, 6 with gPALB2, and 2 with sBRCA2 ).
Bit 27 carries gBRCA2, Bit 7 carries gBRCA1, Bit 6 carries gPALB2, and Bit 2 carries sBRCA2
PFS and OS of the overall queue
PFS and OS of the overall queueThe PFS6 was 59.
The PFS6 was 59.
Best remission in 36 patients with measurable disease
Best remission in 36 patients with measurable diseaseThe PFS at 12 months was 54.
The ORR of 36 patients with measurable diseases was 41.
PFS (panel A) and OS (panel B) in patients with different mutations
PFS (panel A) and OS (panel B) in patients with different mutationsRemission occurred in patients with gBRCA2 (41%, 11/27), gPALB2 (50%, 3/6), and sBRCA2 (50%, 1/2).
In summary, Rucapriel maintenance therapy for platinum-sensitive advanced pancreatic cancer patients carrying pathogenic mutations of BRCA1, BRCA2 or PALB2 has a good curative effect and good safety .
Rucapari maintenance therapy is effective for platinum-sensitive advanced pancreatic cancer patients carrying pathogenic mutations of BRCA1, BRCA2 or PALB2 genes.
Original source:
Kim A.
org/10.
1200/JCO.
21.
00003">Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
in this message
